These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 37464112)

  • 21. FDG-PET imaging for lymph node staging and pathologic tumor response after neoadjuvant treatment of non-small cell lung cancer.
    Ohtsuka T; Nomori H; Ebihara A; Watanabe K; Kaji M; Naruke T; Suemasu K; Uno K
    Ann Thorac Cardiovasc Surg; 2006 Apr; 12(2):89-94. PubMed ID: 16702929
    [TBL] [Abstract][Full Text] [Related]  

  • 22. FDG-PET in staging and restaging non-small cell lung cancer after neoadjuvant chemoradiotherapy: correlation with histopathology.
    Ryu JS; Choi NC; Fischman AJ; Lynch TJ; Mathisen DJ
    Lung Cancer; 2002 Feb; 35(2):179-87. PubMed ID: 11804691
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Metabolic tumor heterogeneity analysis by F-18 FDG PET/CT predicts mediastinal lymph node metastasis in non-small cell lung cancer patients with clinically suspected N2.
    Pahk K; Chung JH; Yi E; Kim S; Lee SH
    Eur J Radiol; 2018 Sep; 106():145-149. PubMed ID: 30150037
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical Characteristics and Outcome of Pathologic N0 Non-small Cell Lung Cancer Patients With False Positive Mediastinal Lymph Node Metastasis on FDG PET-CT.
    Kim KY; Park HL; Kang HS; Lee HY; Yoo IR; Lee SH; Yeo CD
    In Vivo; 2021; 35(3):1829-1836. PubMed ID: 33910869
    [TBL] [Abstract][Full Text] [Related]  

  • 25. When is it best to repeat a 2-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography scan on patients with non-small cell lung cancer who have received neoadjuvant chemoradiotherapy?
    Cerfolio RJ; Bryant AS
    Ann Thorac Surg; 2007 Oct; 84(4):1092-7. PubMed ID: 17888953
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prospective comparative study of integrated positron emission tomography-computed tomography scan compared with remediastinoscopy in the assessment of residual mediastinal lymph node disease after induction chemotherapy for mediastinoscopy-proven stage IIIA-N2 Non-small-cell lung cancer: a Leuven Lung Cancer Group Study.
    De Leyn P; Stroobants S; De Wever W; Lerut T; Coosemans W; Decker G; Nafteux P; Van Raemdonck D; Mortelmans L; Nackaerts K; Vansteenkiste J
    J Clin Oncol; 2006 Jul; 24(21):3333-9. PubMed ID: 16849747
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Accuracy of nodal staging by 18F-FDG-PET/CT in limited disease small-cell lung cancer.
    Hockmann J; Hautzel H; Darwiche K; Eberhard W; Stuschke M; Aigner C; Herrmann K; Plönes T
    Asian Cardiovasc Thorac Ann; 2023 Jul; 31(6):506-511. PubMed ID: 37438928
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Utility of PET/CT for mediastinal staging of non-small cell lung cancer in stage III (N2)].
    Sánchez Sánchez R; Rodríguez Fernández A; Gómez Río M; Alkurdi Martínez A; Castellón Rubio VE; Ramos Font C; Sánchez-Palencia Ramos A; Delgado Pérez JR; Llamas Elvira JM
    Rev Esp Med Nucl; 2011; 30(4):211-6. PubMed ID: 21514978
    [TBL] [Abstract][Full Text] [Related]  

  • 29. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Combining independent studies of diagnostic fluorodeoxyglucose positron-emission tomography and computed tomography in mediastinal lymph node staging for non-small cell lung cancer.
    Alongi F; Ragusa P; Montemaggi P; Bona CM
    Tumori; 2006; 92(4):327-33. PubMed ID: 17036525
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prediction of Advanced Axillary Lymph Node Metastases (ypN2-3) Using Breast MR imaging and PET/CT after Neoadjuvant Chemotherapy in Invasive Ductal Carcinoma Patients.
    Kim WH; Lee SW; Kim HJ; Chae YS; Jeong SY; Jung JH; Park HY; Lee WK
    Sci Rep; 2018 Feb; 8(1):3181. PubMed ID: 29453385
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Improving diagnostic performance of
    Yang DD; Mirvis E; Goldring J; Patel ARC; Wagner T
    Clin Radiol; 2019 Oct; 74(10):818.e17-818.e23. PubMed ID: 31420186
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Is FDG-PET/CT used correctly in the combined approach for nodal staging in NSCLC patients?
    Simsek FS; Comak A; Asik M; Kuslu D; Balci TA; Ulutas H; Koroglu R; Kekilli E; Akatli A; Elmali F; Yalcin NC; Akyol H
    Niger J Clin Pract; 2020 Jun; 23(6):842-847. PubMed ID: 32525121
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical value of F18-fluorodeoxyglucose positron emission tomography-computed tomography in patients with non-small cell lung cancer after potentially curative surgery: experience with 241 patients.
    Kanzaki R; Higashiyama M; Maeda J; Okami J; Hosoki T; Hasegawa Y; Takami M; Kodama K
    Interact Cardiovasc Thorac Surg; 2010 Jun; 10(6):1009-14. PubMed ID: 20197344
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Significance of a new fluorodeoxyglucose-positive lesion on restaging positron emission tomography/computed tomography after induction therapy for non-small-cell lung cancer.
    Collaud S; Lardinois D; Tischler V; Steinert HC; Stahel R; Weder W
    Eur J Cardiothorac Surg; 2012 Mar; 41(3):612-6. PubMed ID: 22219415
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dual-time point
    Park S; Paeng JC; Kang CH; Cheon GJ; Kang KW; Chung JK; Lee DS
    Eur J Nucl Med Mol Imaging; 2018 Jul; 45(8):1317-1328. PubMed ID: 29502309
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mediastinal lymph node staging with FDG-PET scan in patients with potentially operable non-small cell lung cancer: a prospective analysis of 50 cases. Leuven Lung Cancer Group.
    Vansteenkiste JF; Stroobants SG; De Leyn PR; Dupont PJ; Verschakelen JA; Nackaerts KL; Mortelmans LA
    Chest; 1997 Dec; 112(6):1480-6. PubMed ID: 9404742
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical Predictors of Nodal Metastases in Peripherally Clinical T1a N0 Non-Small Cell Lung Cancer.
    Ghaly G; Rahouma M; Kamel MK; Nasar A; Harrison S; Nguyen AB; Port J; Stiles BM; Altorki NK; Lee PC
    Ann Thorac Surg; 2017 Oct; 104(4):1153-1158. PubMed ID: 28551047
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Lymph node staging in non-small cell lung cancer: evaluation by [18F]FDG positron emission tomography (PET).
    Guhlmann A; Storck M; Kotzerke J; Moog F; Sunder-Plassmann L; Reske SN
    Thorax; 1997 May; 52(5):438-41. PubMed ID: 9176535
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mediastinal staging in Non-Small-Cell Lung Carcinoma: computed tomography versus F-18-fluorodeoxyglucose positron-emission tomography and computed tomography.
    Harders SW; Madsen HH; Hjorthaug K; Arveschoug AK; Rasmussen TR; Meldgaard P; Hoejbjerg JA; Pilegaard HK; Hager H; Rehling M; Rasmussen F
    Cancer Imaging; 2014 Jun; 14(1):23. PubMed ID: 25608616
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.